Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of geraniin in preparation of stent coating medicine

A technology of geraniin and coating, which is applied in the field of biomedicine and can solve problems such as unfavorable prognosis

Inactive Publication Date: 2021-08-27
KUNMING MEDICAL UNIVERSITY
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Clinically, clopidogrel and aspirin are generally taken orally after PCI to prevent the occurrence of ISR. Although there is a certain effect, the prognosis of acute coronary events caused by ISR is still not optimistic.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of geraniin in preparation of stent coating medicine
  • Application of geraniin in preparation of stent coating medicine
  • Application of geraniin in preparation of stent coating medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0024] This example provides experiments on the inhibition of VSMCSs proliferation, migration and apoptosis induction by geraniin

[0025] 1. VSMCs culture and passage

[0026] (1) Human umbilical artery-derived VSMCs were purchased from Shanghai Hufeng Biotechnology Co., Ltd. In order to prevent the experimental results from being affected by excessive passage times and changes in cell properties, earlier cells were mostly used in the literature: 3-8 generation VSMCs. In this experiment Cells at passage 4-10 with good growth were selected for experiments.

[0027] VSMCs were cultured in complete DMEM medium containing 10% fetal bovine serum at 37°C, 5% CO 2 , 95% saturated humidity in CO 2 cultured in an incubator. After the cells are 80%-90% confluent, discard the culture medium, wash with PBS three times, add 0.25% trypsin to digest, shake and tap the culture flask gently to remove the cells from the bottle wall, and observe under the microscope. When the cells shrink and...

Embodiment 3

[0072] Establishment of preclinical porcine coronary stent model and OCT examination

[0073] 1. Grouping of Minipigs, Handling

[0074] (1) 20 miniature pigs were randomly and equally divided into negative control group (bare metal stent, BMS), geraniin low-dose stent group (0.4 μg / mm 2 ), geraniin medium-dose stent group (0.8μg / mm 2 ), geraniin high-dose stent group (2.0μg / mm 2 ), the positive control group (sirolimus-eluting stent, SES), and record the numbers marked on the miniature pigs.

[0075] (2) Coronary angiography and stent implantation coronary angiography

[0076]After general anesthesia, the experimental animals underwent left and right coronary angiography through the right femoral artery or left femoral artery. circumflex, LCX) were implanted with one stent of the same type, and the stent-vessel diameter ratio was 1.1-1.2:1. OCT technology was used to observe the stent adherence, and optical coherence tomography was performed at the same time. Coronary ang...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of geraniin in stent coating medicines, and belongs to the technical field of biological medicines. By establishing an in-vitro vascular epidermal growth factor (EGF)-induced smooth muscle cell (VSMCs) proliferation model, the result proves that the geraniin can inhibit proliferation and migration of VSMCs and induce apoptosis of smooth muscle cells at the same time. In order to further verify the value of the geraniin in prevention of intra-stent restenosis (ISR) after percutaneous intracavitary coronary intervention (PCI), a preclinical pig coronary stent model is established, and research results prove that the geraniin coated stent can effectively inhibit pig coronary intimal hyperplasia and shows good histocompatibility and safety. The invention provides theoretical basis and experimental support for clinical application of the geraniin as a natural-source drug stent coating in prevention and treatment of PCI postoperative ISR.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of geraniin in the preparation of drugs for stent coating. Background technique [0002] Atherosclerosis (AS) is a systemic lesion involving large and medium elastic and muscular arteries, and is the main cause of cardiovascular and cerebrovascular diseases such as myocardial infarction and cerebrovascular accident. Coronary atherosclerotic heart disease, referred to as coronary heart disease, is a common and frequently-occurring disease in vascular diseases and seriously endangers human health. Percutaneous coronary intervention (PCI) has become the main method for the treatment of coronary heart disease and one of the main methods for revascularization of coronary heart disease. However, postoperative intra-stent restenosis (PCI) , ISR) limits its application to a certain extent. Although the placement of stents can prevent the elastic recoil of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61L31/16A61L31/08A61K31/7048A61K36/47A61P9/10
CPCA61L31/16A61L31/08A61K31/7048A61K36/47A61P9/10A61L2300/606A61L2300/422A61L2300/23
Inventor 陈鹏沈志强张莉喻卓杨仁华李璠何波杨永兆金浩楠
Owner KUNMING MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com